Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Ev

Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 11, 2023--

Related Keywords

United Kingdom , Massachusetts , United States , Spain , France , Germany , Australia , Turkey , Chile , Poland , Belgium , Israel , Portugal , Canada , Greece , Italy , Lavina Talukdar , Peter Dannenbaum , Luke Mircea Willats , Kyle Holen , Damini Chokshi , Julie Cunningham , Instagram , Moderna Inc , Exchange Commission , Merck Co Inc , International Media Relations Communications , Linkedin , Twitter , Nasdaq , Merck Research Laboratories , Youtube , Statement Of Merck Co Inc , Head Of Development , Facebook , Marjorie Green , Merck Research , Senior Vice President , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse , Which Can Present With Diabetic , Nervous System , Connective Tissue , Patients With Multiple , Neck Squamous Cell , Mismatch Repair Deficient , Mismatch Repair Deficient Colorectal , Looking Statement , Securities Litigation Reform Act , Annual Report , Private Securities Litigation Reform Act , Prescribing Information , Medication Guide , Merck Media Contacts , Investor Contacts , Media Contacts , International Media Relations , Vice President , Business Wire , National Business ,